HC Wainwright Estimates Geron’s Q3 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Investment analysts at HC Wainwright issued their Q3 2024 EPS estimates for shares of Geron in a research report issued to clients and investors on Tuesday, November 5th. HC Wainwright analyst E. Bodnar anticipates that the biopharmaceutical company will post earnings per share of ($0.09) for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Geron’s FY2024 earnings at ($0.36) EPS and FY2025 earnings at ($0.23) EPS.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). The business had revenue of $0.88 million for the quarter, compared to analyst estimates of $0.34 million. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The company’s revenue was up 2941.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.09) EPS.

A number of other brokerages have also issued reports on GERN. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of Geron in a report on Friday, August 9th. Scotiabank started coverage on shares of Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Geron in a research report on Thursday, August 8th. StockNews.com raised shares of Geron to a “sell” rating in a research report on Monday, August 5th. Finally, Leerink Partners started coverage on shares of Geron in a research report on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.05.

Geron Price Performance

Shares of Geron stock opened at $4.22 on Wednesday. The firm has a market cap of $2.54 billion, a PE ratio of -11.72 and a beta of 0.52. Geron has a 12-month low of $1.64 and a 12-month high of $5.34. The company has a quick ratio of 3.60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12. The company’s fifty day simple moving average is $4.33 and its two-hundred day simple moving average is $4.30.

Institutional Investors Weigh In On Geron

Hedge funds have recently bought and sold shares of the business. Darwin Global Management Ltd. bought a new stake in Geron during the second quarter worth about $106,185,000. Tokio Marine Asset Management Co. Ltd. bought a new stake in Geron during the first quarter worth about $333,000. Renaissance Technologies LLC bought a new stake in Geron during the second quarter worth about $3,315,000. Price T Rowe Associates Inc. MD boosted its stake in Geron by 999.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company’s stock worth $6,815,000 after acquiring an additional 1,877,184 shares in the last quarter. Finally, Algert Global LLC bought a new stake in Geron during the second quarter worth about $539,000. Institutional investors own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.